|Videos|March 6, 2023
Considerations for the Treatment of Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Best practices and special considerations for effective therapy selection and sequencing in the relapsed/refractory ALL setting.
Advertisement
Episodes in this series
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
GE HealthCare and Mayo Clinic announced a novel theranostics study to explore a personalized approach to radioligand therapy for advanced prostate cancer.
The FDA has approved pegfilgrastim-pccg, a pegfilgrastim biosimilar, to decrease the incidence of infection in non-myeloid malignancies.
The FDA has approved pembrolizumab plus enfortumab vedotin in MIBC.
Risvutatug rezetecan met the primary OS end point of the phase 3 ARTEMIS-008 trial in Chinese patients with relapsed small-cell lung cancer.
The FDA approved subcutaneous isatuximab delivered via an on-body injector for multiple myeloma.
A real-world claims analysis linked zanubrutinib to improved time to next treatment and overall survival vs acalabrutinib in relapsed/refractory MCL.
Read a refresh of breast cancer FDA news from June 2026, including several practice-changing approvals and the granting of priority review to a SERD.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Subcutaneous Isatuximab Delivered Via On-Body Delivery System for Multiple Myeloma
2
FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC
3
Zoldonrasib Combinations Show Compelling Antitumor Activity in RAS G12D–Mutant Metastatic PDAC
4
Risvutatug Rezetecan Shows OS Benefit Over Topotecan in Relapsed SCLC
5